Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | TSHR | P16473 | 1/20 | 0.56 |
| ▸ | PDE4A | P27815 | 1/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.34 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fructose SCHEMBL27619943 | 1.00 | CYP2C9 (0.56) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Fructose SCHEMBL6262755 | 1.00 | CYP2C9 (0.56) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Fructose SCHEMBL15993990 | 0.98 | CYP2C9 (0.54) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Fructose SCHEMBL16944031 | 0.97 | CYP2C9 (0.58) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Fructose SCHEMBL20898472 | 0.97 | CYP2C9 (0.58) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Tagatose SCHEMBL23827342 | 0.97 | CYP2C9 (0.58) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Fructose SCHEMBL21114385 | 0.97 | CYP2C9 (0.58) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Tagatose SCHEMBL21816881 | 0.97 | CYP2C9 (0.58) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Tagatose SCHEMBL4035 | 0.97 | CYP2C9 (0.58) | CYP2C9TSHRPDE4ALMNAL3MBTL1 | |
| Fructose SCHEMBL2123235 | 0.97 | CYP2C9 (0.58) | CYP2C9TSHRPDE4ALMNAL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 105 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106574926-B | For predicting the biomarker of weight degree of alleviation | 雀巢产品技术援助有限公司 | 2019-04-19 | — | — | CN | claimed |
| CN-109072302-A | non-invasive diagnosis of non-alcoholic steatohepatitis | 基恩菲特公司 | 2018-12-21 | — | — | CN | claimed |
| CN-108697769-A | Glucagon for treating obesity and GLP-1 co-agonists | 免疫医疗有限公司 | 2018-10-23 | — | — | CN | claimed |
| CN-108138232-A | For diagnosing and assessing the method for nonalcoholic fatty liver disease | 基恩菲特公司 | 2018-06-08 | — | — | CN | claimed |
| CN-108026529-A | Combination treatment | IONIS制药公司 | 2018-05-11 | — | — | CN | claimed |
| CN-107638562-A | The quick foundation and/or termination of basic steady-state drug delivery | 精达制药公司 | 2018-01-30 | — | — | CN | claimed |
| CN-107108710-A | Modified FGF-21 polypeptides and uses thereof | 百时美施贵宝公司 | 2017-08-29 | — | — | CN | claimed |
| EP-2863934-B1 | ADVANCED GLYCATION END PRODUCT ANALOGUES | PHYTOQUEST LTD (GB) | 2017-08-16 | — | — | EP | claimed |
| CN-106574926-A | Biomarkers for predicting degree of weight loss | 雀巢产品技术援助有限公司 | 2017-04-19 | — | — | CN | claimed |
| WO-2016036944-A1 | TRANSDERMAL ANALYTE MONITORING SYSTEMS CORRECTED FOR ON-SKIN AND BREAK-IN CURRENTS | ECHO THERAPEUTICS, INC. (US) | 2016-03-10 | — | — | WO | claimed |
| CN-101505746-A | Treatment of inflammatory conditions | DYNAMIS THERAPEUTICS INC (US) | 2009-08-12 | — | — | CN | claimed |
| CN-101084235-A | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS INC (US) | 2007-12-05 | — | — | CN | claimed |
| US-6503198-B1 | Noninvasive transdermal systems for detecting an analyte obtained from or underneath skin and methods | ARONOWITZ, JACK L. | 2003-01-07 | — | — | US | claimed |
| JP-1108997-A | — | — | None | — | — | JP | disclosed |
| JP-1108997-A | — | — | None | — | — | JP | disclosed |
| CN-110366426-A | A method of promoting insulin secretion | 泰伦基国际有限公司 | 2019-10-22 | — | — | CN | disclosed |
| US-5736400-A | Method for modifying, diagnosing and screening for IGF-I sensitive cell barriers | MOSES ALAN C (US) | 1998-04-07 | — | — | US | disclosed |
| US-5637567-A | EXPOSURE TO SOMATOMEDINS | THE BETH ISRAEL HOSPITAL ASSOCIATION (US) | 1997-06-10 | — | — | US | disclosed |
| JP-H01108997-A | SPECIFIC DETERMINATION OF FRUCTOSE AMINE CONTENT IN SERUM IN BLOOD OR SPECIMEN DERIVED FROM BLOOD, AND REMOVAL OF COMPONENT HAVING NON SPECIFIC REDUCING ACTION AND/OR CAUSING TURBIDITY IN SPECIMEN | BOEHRINGER MANNHEIM GMBH | 1989-04-26 | — | — | JP | disclosed |
| JP-H01108997-A | SPECIFIC DETERMINATION OF FRUCTOSE AMINE CONTENT IN SERUM IN BLOOD OR SPECIMEN DERIVED FROM BLOOD, AND REMOVAL OF COMPONENT HAVING NON SPECIFIC REDUCING ACTION AND/OR CAUSING TURBIDITY IN SPECIMEN | BOEHRINGER MANNHEIM GMBH | 1989-04-26 | — | — | JP | disclosed |